Cd20-directed serotherapy in patients with multiple myeloma: Biologic considerations and therapeutic applications

Journal of Immunotherapy

Volumn 25, Issue 1, 2002, Pages 72-81

  Treon, Steven P ^a   Pilarski, Linda M ^a   Belch, Andrew R ^a   Kelliher, Abigail ^a   Preffer, Frederic I ^a   Shima, Yoshihito ^b   Mitsiades, Constantine S ^b   Mitsiades, Nicholas S ^b   Szczepek, Agnieszka J ^b   Ellman, Leonard ^b   Harmon, David ^b   Grossbard, Michael L ^b   Anderson, Kenneth C ^b  

^a DANA FARBER CANCER INSTITUTE   (United States)

^b UNIVERSITY OF ALBERTA   (Canada)

Author keywords

B cells; CD20; Interferongamma; Multiple myeloma; Rituximab

Indexed keywords

CD20 ANTIGEN; GAMMA INTERFERON; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY CD20; RITUXIMAB; UNCLASSIFIED DRUG;

ADULT; AGED; ANTIGEN EXPRESSION; ARTICLE; B LYMPHOCYTE; BONE MARROW CELL; CHRONIC LYMPHATIC LEUKEMIA; CLINICAL ARTICLE; CLINICAL TRIAL; CLONOGENESIS; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG TOLERABILITY; FEMALE; HUMAN; HUMAN CELL; MALE; MULTIPLE MYELOMA; NONHODGKIN LYMPHOMA; PHASE 2 CLINICAL TRIAL; PLASMA CELL; PRIORITY JOURNAL; SIGNAL TRANSDUCTION; STEM CELL; TREATMENT FAILURE; TREATMENT OUTCOME;

ADULT; AGED; AGED, 80 AND OVER; ANTIBODIES, MONOCLONAL; ANTIGENS, CD20; ANTINEOPLASTIC AGENTS; FEMALE; HUMANS; IMMUNIZATION, PASSIVE; INTERFERON TYPE II; MALE; MIDDLE AGED; MULTIPLE MYELOMA; PLASMA CELLS; RECEPTORS, INTERFERON;

EID: 0036140240     PISSN: 15249557     EISSN: 15374513     Source Type: Journal    
DOI: 10.1097/00002371-200201000-00008     Document Type: Article

References (69)

1. Anderson KC, Bates MP, Slaughenhoupt BL, et al: Expression of human B cell-associated antigens on leukemias and lymphomas: a model of human B cell differentiation. Blood 1984; 63: 1424-33.
2. Hokland P, Ritz J, Schlossman SF, et al. Orderly progression of B-cell antigens during the in vitro differentiation of non-malignant human pre-B cells. J Immunol 1985; 135: 1746-51.
3. Treon SP, Anderson KC. The use of rituximab in the treatment of malignant and non-malignant plasma cell disorders. Semin Oncol 2000; 27: 79-85.
4. Scott EW, Simon MC, Anastasi J, et al: Requirement of transcription factor PU.1 in the development of multiple hematopoietic lineages. Science 1994; 265: 1573-7.
5. Himmelmann A, Riva A, Wilson GL, et al. PU.1/Pip and basic helix loop helix zipper transcription factors interact with binding sites in the CD20 promoter to help confer lineage- and stage-specific expression of CD20 in B lymphocytes. Blood 1997; 90: 3984-95.
6. Pettersson M, Sundstrom C, Nilsson K, et al. The hematopoietic transcription factor PU.1 is downregulated in human multiple myeloma cell lines. Blood 1995; 86: 2747-59.
7. Billadeau D, Ahmann G, Greipp P, et al. The bone marrow of multiple myeloma patients contains B cell populations at different stages of differentiation that are clonally related to the malignant plasma cell. J Exp Med 1993; 178: 1023-31.
8. Szczepek AJ, Seeberger K, Wizniak J, et al. A high frequency of circulating B cells share clonotypic IgH VDJ rearrangements with autologous bone marrow plasma cells in multiple myeloma, as measured by single cell and in-situ RT-PCR. Blood 1998; 92: 2844-55.
9. + peripheral blood cells expressing CD38, CD56, and monotypic immunoglobulin light chain. Blood 1995; 85: 436-47.
10. Bergsagel PL, Belch AR, Pilarksi LM. The blood B cells and bone marrow plasma cells in a patient with multiple myeloma include cells with the same N -ras mutation. Blood 1994; 84: 524a.
11. + monoclonal B lineage cells in peripheral blood from myeloma patients as late stage B cells. Blood 1991; 78: 711-9.
12. Treon SP, Maimonis P, Bua D, et al. Elevated soluble MUC1 levels and decreased anti-MUC1 antibody levels in patients with multiple myeloma. Blood 2000; 96: 3147-53.
13. Szczepek AJ, Seeberger K, Wizniak J, et al. A high frequency of circulating B cells share clonotypic Ig heavy chain VDJ rearrangements with autologous bone marrow plasma cells in multiple myeloma as measured by single cell and in situ reverse transcriptase-polymerase chain reaction. Blood 1998; 92: 2844-55.
14. + cells in the peripheral blood of a patient with multiple myeloma. Br J Haematol 1999; 105: 265-7.
15. King M, Nelson DS. Tumor cell heterogeneity in multiple myeloma: antigenic, morphologic, and functional studies of cells from blood and bone marrow. Blood 1989; 73: 1925-35.
16. Takashita M, Kosaka M, Goto T, et al. Cellular origin and extent of clonal involvement in multiple myeloma: genetic and phenotypic studies. Br J Haematol 1994; 87: 735-42.
17. + is the common phenotype of myeloma cells. Ann Hematol 1992; 64: 132-9.
18. Garcia-Sanz R, Orfao A, Gonzalez M, et al. Primary plasma cell leukemia: clinical, immunophenotypic, DNA ploidy and cytogenetic characteristics. Blood 1999; 93: 1032-7.
19. Treon SP, Shima Y, Preffer FI, et al. Treatment of plasma cell dyscrasias by antibody mediated immunotherapy. Semin Oncol 1999; 26: 97-106.
20. San Miguel JF, Gonzalez M, Gascon A, et al. Immunophenotypic heterogeneity of multiple myeloma: influence on the biology and clinical course of the disease. Castellano-Leones (Spain) Cooperative Group for the Study of Monoclonal Gammopathies. Br J Haematol 1991; 77: 185-90.
21. Pilarski LM, Masellis-Smith A, Szczepek A, et al. Circulating clonotypic B cells in the biology of multiple myeloma: Speculations on the origin of myeloma. Leuk Lymph 1996; 22: 375.
22. Pilarski LM, Hipperson G, Seeberger K, et al. Myeloma progenitors in the blood of patients with aggressive or minimal disease: engraftment and self-renewal of primary human myeloma in the bone marrow of NOD SCID mice. Blood 2000; 95: 1056-65.
23. Maloney DG, Liles TM, Czerwinski DK, et al. Phase I clinical trial using escalating single-dose infusion of chimeric anti-CD20 monoclonal antibody (IDEC-C2B8) in patients with recurrent B-cell lymphoma. Blood 1994; 84: 2457-66.
24. McLaughlin P, Grillo-Lopez AJ, Link BK, et al. Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program. J Clin Oncol 1998; 16: 2825-33.
25. Coiffier B, Haioun C, Ketterer N, et al. Rituximab (anti-CD20 monoclonal antibody) for the treatment of patients with relapsing or refractory aggressive lymphoma: a multicenter phase II study. Blood 1998; 92: 1927-32.
26. Treon SP, Agus DB, Link B, et al. CD20-directed antibody mediated immunotherapy induces responses and facilitates hematological recovery in patients with Waldenstrom's macroglobulinemia. J Immunother 2001; 24: 272-9.
27. Treon SP, Mollick JA, Urashima M, et al. MUC1 core protein is expressed on multiple myeloma cells and is induced by dexamethasone. Blood 1999; 93: 1287-98.
28. Venugopal P, Sivaraman S, Huang X, et al. Upregulation of CD20 expression in chronic lymphocytic leukemia cells by in vitro exposure to cytokines [Abstract]. Blood 1998; 92: 247.
29. Ozaki S, Kosaka M, Wakahara Y, et al. Interferon-alpha and -gamma enhance the HM1.24 expression on myeloma cells through the STAT-signaling pathway [Abstract]. Blood 1999; 94: 549.
30. Venugopal P, Sivaraman S, Huang XK, et al. Interferon-alpha can augment multiple antigens on the cell surface of lymphoproliferative disorders that can be targeted using monoclonal antibodies [Abstract]. Blood 2000; 96: 297.
31. Reff ME, Carner K, Chambers KS, et al. Depletion of B cells in vivo by a chimeric mouse human monoclonal antibody to CD20. Blood 1994; 83: 435-45.
32. Hariharan D, Douglas SD, Lee B, et al. Interferon- upregulates CCR5 expression in cord and adult blood mononuclear phagocytes. Blood 1999; 93: 1137-44.
33. Gastl G, Ebert T, Finstad CL, et al. Major histocompatibility complex class I and class II expression in renal cell carcinoma and modulation by interferon gamma. J Urol 1996; 155: 361-7.
34. Akbar SM, Inaba K, Onji M. Upregulation of MHC class II antigen on dendritic cells from hepatitis B virus transgenic mice by interferon-gamma: abrogation of immune response defect to a T-cell-dependent antigen. Immunology 1996; 87: 519-27.
35. Schiff DE, Rae J, Martin TR, et al. Increased phagocyte Fc gammaRI expression and improved Fc gamma-receptor-mediated phagocytosis after in vivo recombinant human interferon-gamma treatment of normal human subjects. Blood 1997; 90: 3187-94.
36. Pandita R, Pocsik E, Aggarwal BB. Interferon-gamma induces cell surface expression for both types of tumor necrosis factor receptors. FEBS Lett 1992; 312: 87-90.
37. Ogata A, Nishimoto N, Shima Y, et al. Inhibitory effect of all trans-retinoic acid on the growth of freshly isolated myeloma cells via interference with the interleukin-6 signal transduction. Blood 1994; 84: 3040-6.
38. Shima Y, Nishimoto N, Ogata A, et al. Myeloma cells express Fas antigen/APO-1 (CD95) but only some are sensitive to anti-Fas antibody resulting in apoptosis. Blood 1995; 85: 757-64.
39. Karmann K, Hughes CC, Schechner J, et al. CD40 on human endothelial cells: Inducibility by cytokines and functional regulation of adhesion molecule expression. Proc Natl Acad Sci U S A 1995; 92: 4342-6.
40. Thevenin C, Lucas BP, Kozlow EJ, et al. Cell type and stage specific expression of the CD20/B1 antigen correlates with the activity of a diverged octamer DNA motif present in its promoter. J Biol Chem 1993; 298: 5949-56.
41. Gutierrez P, Delgado MD, Richard C, et al. Interferon induces up-regulation of Spi-1/PU.1 in human leukemia K562 cells. Biochem Biophys Res Comm 1997; 240: 862-8.
42. Reiman T, Seeberger K, Taylor BJ, et al. Persistent pre-switch myeloma cells correlate with decreased survival: evidence for isotype switching within the myeloma clone. Blood 2001; 98: 2791-9.
43. Hussein MA, Elson P, Karam MA, et al. Biologic and clinical evaluation of rituxan in the management of newly diagnosed multiple myeloma patients: an update [Abstract]. Proc Am Soc Clin Oncol 2001; 20: 299a.
44. Pilarski LM, Giannakopoulos NV, Szczepek AJ, et al. In multiple myeloma, circulating hyperdiploid B cells have clonotypic heavy chain rearrangements and may mediate spread of disease. Clin Cancer Res 2000; 6: 585-96.
45. Yaccoby S, Barlogie B, Epstein J. Mature myeloma cells are proliferative with self renewal potential [Abstract]. Blood 1997; 92: 588.
46. Yaccoby S, Johnson CL, Barlogie B, et al. Transfer of myeloma plasma cells but not plasma cell depleted bone marrow and blood cells cause myeloma in healthy hosts. Blood 1998; 92: 261.
47. Pilarski LM, Szczepek AJ, Belch AR. Deficient drug transporter function of bone marrow localized and leukemic plasma cells in multiple myeloma. Blood 2000; 90: 3751-9.
48. Pilarski LM, Mant MJ, Belch AR. Drug resistance in multiple myeloma: novel therapeutic targets within the malignant clone. Leuk Lymph 1999; 32: 199-210.
49. Pilarski LM, Coupland RW, Belch AR. Myeloma progenitors in G-CSF mobilized blood engraft murine bone marrow [Abstract]. Blood 1999; 94: 662.
50. Foon KA, Sherwin SA, Abrams PG, et al. A phase I trial of recombinant gamma interferon in patients with cancer. Cancer Immunol Immunother 1985; 20: 193-7.
51. Kurzock R, Rosenblum MG, Sherwin SA, et al. Pharmacokinetics, single dose tolerance, and biological activity of recombinant -interferon in cancer patients. Cancer Res 1985; 45: 2866-72.
52. Vadhan-Raj S, Al-Katib A, Bhalla R, et al. Phase I trial of recombinant interferon-gamma in cancer patients. J Clin Oncol 1986; 4: 137-46.
53. Onishi T, Machida T, Masuda F, et al. Assessment of tumour infiltrating lymphocytes, regional lymph node lymphocytes and peripheral blood lymphocytes and their reaction to interferon-gamma in patients with renal carcinoma. Br J Urol 1991; 67: 459-66.
54. Ginaldi L, DeMartinis M, Matutes E, et al. Levels of expression of CD19 and CD20 in chronic B cell leukaemias. J Clin Pathol 1998; 51: 364-9.
55. Driggers PH, Ennist DL, Gleason SL, et al. An interferon -regulated protein that binds the interferon-inducible enhancer element of major histocompatibility complex class I genes. Proc Natl Acad Sci U S A 1990; 87: 3743-7.
56. Iida S, Rao PH, Butler M, et al. Deregulation of MUM1/IRF4 by chromosomal translocation in multiple myeloma. Nature Genetics 1997; 17: 226-30.
57. Matsuyama T, Grossman A, Mittrucker HW, et al. Molecular cloning if LSIRF, a lymphoid specific member of the interferon regulatory factor family that binds the interferon-stimulated response element (ISRE). Nucl Acids Res 1995; 23: 2127.
58. Weiner LM, Steplewski Z, Koprowski H, et al. Divergent dose-related effects of gamma-interferon therapy on in vitro antibody dependent cellular and nonspecific cytotoxicity by human peripheral monocytes. Cancer Res 1988; 48: 1042-6.
59. Weiner LM, Moldofsky PJ, Gatenby RA, et al. Antibody delivery and effector cell activation in a phase II trial of recombinant gamma-interferon and the murine monoclonal antibody CO17-1A in advanced colorectal carcinoma. Cancer Res 1988; 48: 2568-73.
60. Ralph P, Nakoinz I, Rennick D. Role of interleukin 2, interleukin 4, and alpha, beta, and gamma interferon in stimulating macrophage antibody-dependent tumoricidal activity. J Exp Med 1988; 167: 712-7.
61. Maluish AE, Urba WJ, Longo DL, et al. The determination of an immunologically active dose of interferon-gamma in patients with melanoma. J Clin Oncol 1988; 6: 434-45.
62. Kurzock R, Quesada JR, Talpaz M, et al. Phase I study of multiple dose intramuscularly administered recombinant gamma interferon. J Clin Oncol 1986; 4: 1101-9.
63. Janakiraman N, McLaughlin P, White CA, et al. Rituximab: Correlation between effector cells and clinical activity in NHL [Abstract]. Blood 1998; 92: 337.
64. Urashima M, Teoh G, Chauhan D, et al. Interleukin-6 overcomes p21 WAF1 upregulation and G1 growth arrest induced by dexamethasone and interferon-gamma in multiple myeloma cells. Blood 1997; 90: 279-89.
65. Einhorn S, Fernberg JO, Grander D, et al. Interferon exerts a cytotoxic effect on primary human myeloma cells. Eur J Cancer Clin Oncol 1988; 24: 1505-10.
66. Jernberg-Wiklund H, Pettersson M, Nilsson K. Recombinant interferon- inhibits the growth of IL-6 dependent human multiple myeloma cell lines in vitro. Eur J Haematol 1991; 46: 231-9.
67. Portier M, Zhang XG, Caron E, et al. Gamma-interferon in multiple myeloma: Inhibition of interleukin 6 dependent myeloma cell growth and downregulation of IL-6 receptor expression in vitro. Blood 1993; 81: 3076-82.
68. Treon SP, Anderson KC. Interleukin 6 in multiple myeloma and related plasma cell dyscrasias. Curr Opin Hematol 1998; 5: 42-8.
69. Kobayashi Y, Urabe A. Gamma-interferon therapy of cancer patients. Jap J Cancer Chemother 1988; 15: 804.